RT Journal Article
SR Electronic
T1 Variants in the Niemann-Pick type C gene <em>NPC1</em> are not associated with Parkinson’s disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.06.20030734
DO 10.1101/2020.03.06.20030734
A1 Amar Bencheikh, Bouchra Ouled
A1 Senkevich, Konstantin
A1 Rudakou, Uladzislau
A1 Yu, Eric
A1 Mufti, Kheireddin
A1 Ruskey, Jennifer A.
A1 Asayesh, Farnaz
A1 Laurent, Sandra B.
A1 Spiegelman, Dan
A1 Fahn, Stanley
A1 Waters, Cheryl
A1 Monchi, Oury
A1 Dauvilliers, Yves
A1 Espay, Alberto J.
A1 Dupré, Nicolas
A1 Greenbaum, Lior
A1 Hassin-Baer, Sharon
A1 Rouleau, Guy A.
A1 Alcalay, Roy N.
A1 Fon, Edward A.
A1 Gan-Or, Ziv
YR 2020
UL http://medrxiv.org/content/early/2020/03/08/2020.03.06.20030734.abstract
AB Biallelic variants in NPC1, a lysosomal gene coding for a transmembrane protein involved in cholesterol trafficking, may cause Niemann-Pick disease type C (NPC). A few cases of NPC1 mutation carriers have been reported with a Parkinson’s disease (PD) presentation. In addition, pathological studies demonstrated phosphorylated alpha-synuclein and Lewy pathology in brains of NPC patients. Therefore, we aimed to examine whether NPC1 genetic variants may be associated with PD. Full sequencing of NPC1 was performed in 2,657 PD patients and 3,647 controls from three cohorts, using targeted sequencing with molecular inversion probes. A total of 9 common variants and 126 rare variants were identified across the three cohorts. To examine association with PD, regression models adjusted for age, sex and origin were performed for common variants, and optimal sequence Kernel association test (SKAT-O) was performed for rare variants. After correction for multiple comparisons, common and rare NPC1 variants were not associated with PD. Our results do not support a link between heterozygous variants in NPC1 and PD.Competing Interest StatementZiv Gan-Or has received consulting fees from Lysosomal Therapeutics Inc., Idorsia, Prevail Therapeutics, Denali, Ono Therapeutics, Deerfield and Inception Sciences (now Ventus). Alberto Espay has received grant support from the NIH and the Michael J Fox Foundation; personal compensation as a consultant/scientific advisory board member for Abbvie, Neuroderm, Neurocrine, Amneal, Adamas, Acadia, Acorda, InTrance, Sunovion, Lundbeck, and USWorldMeds; publishing royalties from Lippincott Williams &amp; Wilkins, Cambridge University Press, and Springer; and honoraria from USWorldMeds, Acadia, and Sunovion. Dr. Alcalay received consultation fees for Sanofi, Roche, Janssen and Restorbio. None of these companies were involved in any parts of preparing, drafting and publishing this study.Funding StatementWe thank the participants for contributing to the study. This work was financially supported by grants from the Michael J. Fox Foundation, the Canadian Consortium on Neurodegeneration in Aging (CCNA), the Canada First Research Excellence Fund (CFREF), awarded to McGill University for the Healthy Brains for Healthy Lives initiative (HBHL), and Parkinson Canada. The Columbia University cohort is supported by the Parkinson’s Foundation, the National Institutes of Health (K02NS080915, and UL1 TR000040) and the Brookdale Foundation. KS is supported by a post-doctoral fellowship from the Canada First Research Excellence Fund (CFREF), awarded to McGill University for the Healthy Brains for Healthy Lives initiative (HBHL). GAR holds a Canada Research Chair in Genetics of the Nervous System and the Wilder Penfield Chair in Neurosciences. EAF is supported by a Foundation Grant from the Canadian Institutes of Health Research (FDN grant - 154301). ZGO is supported by the Fonds de recherche du Québec - Santé (FRQS) Chercheurs-boursiers award, in collaboration with Parkinson Quebec, and by the Young Investigator Award by Parkinson Canada. OM holds the Canada Research Chair in non-motor symptoms of Parkinson’s disease and the Tourmaline Chair in Parkinson’s disease.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data in the manuscript is available upon request